A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
A Phase 3 Randomized, Double-Blind Study of PF-05280014 Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel for the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Category & Conditions: Cancer
Medicine: TRAZIMERA FOR INJECTION(TRASTUZUMAB-QYYP)
ClinicalTrials.gov Identifier (NCT): NCT01989676
Protocol ID: B3271002
PrintDownloadOpen Plain Language Summary Result: Click here